Early virologic response after peginterferon alpha-2a plus ribavirin or peginterferon alpha-2b plus ribavirin treatment in patients with chronic hepatitis C

Journal of Viral Hepatitis

Volumn 14, Issue 10, 2007, Pages 721-729

  Di Bisceglie, A M ^a,e   Ghalib, R H ^b   Hamzeh, F M ^c   Rustgi, V K ^d  

^a SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b METHODIST DALLAS MEDICAL CENTER   (United States)

^c HOFFMANN LA ROCHE INC   (United States)

^d GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

^e Saint Louis University   (United States)

Author keywords

Genotype 1; Hepatitis C virus; High viral load; Peginterferon alpha 2a; Peginterferon alpha 2b; Ribavirin; Virologic response

Indexed keywords

PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN; VIRUS RNA;

ADULT; ANEMIA; ANOREXIA; ANXIETY; ARTHRALGIA; ARTICLE; BACKACHE; BLURRED VISION; CHILL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DEPRESSION; DIARRHEA; DIZZINESS; DOSE RESPONSE; DRUG ACTIVITY; DRUG DOSE REDUCTION; DRUG SAFETY; DRUG WITHDRAWAL; DRY SKIN; DYSGEUSIA; DYSPNEA; ERYTHEMA; FATIGUE; FEMALE; FEVER; FLU LIKE SYNDROME; GENOTYPE; HEADACHE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; INJECTION SITE REACTION; INSOMNIA; IRRITABILITY; ISCHEMIC COLITIS; MAJOR CLINICAL STUDY; MALE; MYALGIA; NAUSEA; NEUTROPENIA; NONHUMAN; PAIN; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RASH; SIDE EFFECT; SUICIDAL IDEATION; SYNCOPE; THROMBOCYTOPENIA; UPPER ABDOMINAL PAIN; VIROLOGY; VIRUS LOAD; VOMITING;

ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; FEMALE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2A; INTERFERON ALFA-2B; INTERFERONS; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; RIBAVIRIN; RNA, VIRAL; TIME FACTORS; VIRAL LOAD;

EID: 34548660545     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/j.1365-2893.2007.00862.x     Document Type: Article

References (24)

1. Strader DB, Wright T, Thomas DL, Seeff LB. American Association for the Study of Liver Diseases practice guideline: diagnosis, management, and treatment of hepatitis C. Hepatology 2004 39 : 1147 1171.
2. Hoofnagle JH. Hepatitis C: the clinical spectrum of disease. Hepatology 1997 26 (Suppl. 1 15S 20S.
3. Pockros PJ. Developments in the treatment of chronic hepatitis C. Expert Opin Investig Drugs 2002 11 : 515 528.
4. McHutchison JG, Shad JA, Gordon SC et al. Predicting response to initial therapy with interferon plus ribavirin in chronic hepatitis C using serum HCV RNA results during therapy. J Viral Hepat 2001 8 : 414 420.
5. Fried MW, Shiffman ML, Reddy KR et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002 347 : 975 982.
6. Davis GL, Wong JB, McHutchison JG, Manns MP, Harvey J, Albrecht J. Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C. Hepatology 2003 38 : 645 652.
7. Lee SS, Heathcote EJ, Reddy KR et al. Prognostic factors and early predictability of sustained viral response with peginterferon alfa-2a (40 KD). J Hepatol 2002 37 : 500 506.
8. Hadziyannis SJ, Sette H Jr., Morgan TR et al. Peginterferon-α-2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004 140 : 346 355.
9. Bailon P, Palleroni A, Schaffer CA et al. Rational design of a potent, long-lasting form of interferon: a 40 kDa branched polyethylene glycol-conjugated interferon α-2a for the treatment of hepatitis C. Bioconjug Chem 2001 12 : 195 202.
10. Glue P, Fang JWS, Rouzier-Panis R et al. and the Hepatitis C Intervention Therapy Group. Pegylated interferon-α2b: pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data. Clin Pharmacol Ther 2000 68 : 556 567.
11. Wang Y-S, Youngster S, Bausch J, Zhang R, McNemar C, Wyss DF. Identification of the major positional isomer of pegylated interferon alpha-2b. Biochemistry 2000 39 : 10634 10640.
12. Luxon BA, Grace M, Brassard D, Bordens R. Pegylated interferons for the treatment of chronic hepatitis C infection. Clin Ther 2002 24 : 1363 1383.
13. Glue P, Rouzier-Panis R, Raffanel C et al. and the Hepatitis C Intervention Therapy Group. A dose-ranging study of pegylated interferon alfa-2b and ribavirin in chronic hepatitis C. Hepatology 2000 32 : 647 653.
14. Buti M, Sanchez-Avila F, Lurie Y et al. Viral kinetics in genotype 1 chronic hepatitis C patients during therapy with 2 different doses of peginterferon alfa-2b plus ribavirin. Hepatology 2002 35 : 930 936.
15. Jessner W, Watkins-Riedel T, Formann E, Steindl-Munda P, Ferenci P. Hepatitis C viral dynamics: basic concept and clinical significance [review]. J Clin Virol 2002 25 : S31 S39.
16. Formann E, Jessner W, Bennett L, Ferenci P. Twice-weekly administration of peginterferon-α-2b improves viral kinetics in patients with chronic hepatitis C genotype 1. J Viral Hepat 2003 10 : 271 276.
17. Herrmann E, Lee J-H, Marinos G, Modi M, Zeuzem S. Effect of ribavirin on hepatitis C viral kinetics in patients treated with pegylated interferon. Hepatology 2003 37 : 1351 1358.
18. Bruno R, Sacchi P, Ciappina V et al. Viral dynamics and pharmacokinetics of peginterferon alpha-2a and peginterferon alpha-2b in naive patients with chronic hepatitis C: a randomized, controlled study. Antivir Ther 2004 9 : 491 497.
19. Silva M, Poo-Ramirez J-L, Wagner F, Jackson M, Laughlin M. Comparison of peginterferon-α2a and peginterferon-α2b pharmacokinetics and pharmacodynamic in COMPARE, a randomized, prospective, blinded trial [abstract]. Hepatology 2004 40 : 192A. Abstract 68.
20. Ferenci P, Fried MW, Shiffman ML et al. Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/ribavirin. J Hepatol 2005 43 : 425 433.
21. Jensen DM, Morgan TR, Marcellin P et al. Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon α-2a (40 kd)/ribavirin therapy. Hepatology 2006 43 : 954 960.
22. Layden TJ, Layden JE, Reddy KR, Levy-Drummer RS, Poulakos J, Neumann AU. Induction therapy with consensus interferon (CIFN) does not improve sustained virologic response in chronic hepatitis C. J Viral Hepat 2002 9 : 334 339.
23. Ferenci P. Predicting the therapeutic response in patients with chronic hepatitis C: the role of viral kinetic studies. J Antimicrob Chemother 2004 53 : 15 18.
24. Manns MP, McHutchison JG, Gordon SC et al. and the International Hepatitis Interventional Therapy Group. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001 358 : 958 965.